Niki BioSolutions (NIKI) vs Tungray Technologies (TRSG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tungray Technologies (TRSG) has outperformed Niki BioSolutions (NIKI) over the past year, losing 16.1% versus a loss of 82.1%. Tungray Technologies is the larger company by market cap ($19.1 million vs $12.8 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NIKI | TRSG |
|---|---|---|
| Share price | $4.10 | $1.17 |
| Market cap | $12.79M | $19.06M |
| 1-day change | -5.09% | 0.00% |
| YTD return | -59.25% | +4.37% |
| 1-year return | -82.07% | -16.13% |
| 5-year return | -98.33% | — |
| EPS (TTM) | $-2.90 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.00 | $1.75 |
| 52-week low | $4.00 | $1.00 |
| Distance from 52-week high | -82.92% | -33.38% |
| Average volume | 157.52K | 22.85K |
| Shares outstanding | 2.94M | 11.79M |
| Employees | 1 | 240 |
| Sector | Industrials | Industrials |
| Industry | Industrial Machinery/Components | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRSG has outperformed NIKI by 65.9 percentage points over the past year.
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
About Tungray Technologies
TRSG stock →Tungray Technologies Inc., an engineer-to-order company, through its subsidiaries, provides tooling solutions and customized industrial manufacturing solutions in China and Singapore. It offers customized industrial test and tooling solutions; welding equipment manufacturing; and direct drive and linear direct current motors.
Industrials · Industrial Machinery/Components · 240 employees
NIKI vs TRSG FAQ
Which is bigger, Niki BioSolutions or Tungray Technologies?
Tungray Technologies (TRSG) is larger, with a market capitalization of $19.06M compared with $12.79M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, NIKI or TRSG?
TRSG returned -16.13% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Niki BioSolutions and Tungray Technologies in the same industry?
Yes. Both are classified in the Industrial Machinery/Components industry within the Industrials sector.